文献速递临床试验与 GCP真实世界研究与卫生经济

晚期肝硬化难治性腹水患者姑息性长期腹腔引流与反复引流比较:可行性随机对照试验研究方案

Palliative long-term abdominal drains versus repeated drainage in individuals with untreatable ascites due to advanced cirrhosis: study protocol for a feasibility randomised controlled trial.
PubMed 文献 · Trials · 2018-07-27

英国因肝硬化等慢性肝病死亡人数40年间翻两番,晚期肝硬化难治性腹水患者平均预期寿命≤6个月,频繁住院引流不适宜。本研究设计可行性随机对照试验,计划招募48例难治性腹水患者,1:1随机分配至长期腹腔引流(LTAD)或现行标准治疗(大量腹腔穿刺放液,LVP)12周,评估LTAD可接受性、招募与保留率及初步成本效果,为后续确证性试验设计提供依据。

要点

  • 晚期肝硬化难治性腹水患者预期寿命平均≤6个月,频繁住院LVP不适宜。
  • LTAD已在恶性腹水患者中成功使用,但未在肝硬化难治性腹水中正式评估。
  • 本可行性RCT计划招募48例,1:1随机至LTAD或LVP,干预12周。

核心结论

  • LTAD可能通过改善症状控制、减少就医次数并允许部分自我管理来改善晚期肝硬化难治性腹水患者的终末期照护。
  • 本试验旨在评估此类患者能否被招募,并为后续确证性试验的设计提供信息。

研究设计与样本

  • 可行性随机对照试验,计划招募48例难治性腹水患者,1:1随机分配至LTAD组或现行标准治疗(LVP)组,干预12周。
  • 试验设计前已咨询患者对研究设计的意见。

关键数值与推荐

  • 主要关注LTAD对患者、照护者及医护人员的可接受性,以及招募率和保留率。
  • 将评估整合姑息照护结局量表(IPOS)、短版肝病生活质量问卷、EuroQol 5维度工具及照护者报告的Zarit负担访谈等结局。
  • 将收集初步成本效果数据,并访谈患者和医护人员以识别招募障碍。

临床怎么用

  • LTAD为晚期肝硬化难治性腹水患者提供了一种可在医院外管理腹水的潜在选择,减少住院需求。
  • 当前证据尚限于可行性试验阶段,LTAD在ESLD难治性腹水中的正式疗效与安全性有待后续确证性试验验证。

局限性

  • 本研究为可行性试验,样本量48例,主要目的为评估招募、保留及可接受性,非确证疗效。
  • LTAD尚未在晚期肝硬化难治性腹水患者中经过正式评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: UK deaths due to chronic liver diseases such as cirrhosis have quadrupled over the last 40 years, making this condition now the third most common cause of premature death. Most patients with advanced cirrhosis (end-stage liver disease [ESLD]) develop ascites. This is often managed with diuretics, but if refractory, then the fluid is drained from the peritoneal cavity every 10-14 days by large volume paracentesis (LVP), a procedure requiring hospital admissions. As the life expectancy of patients with ESLD and refractory ascites (if ineligible for liver transplantation) is on average ≤ 6 months, frequent hospital visits are inappropriate from a palliative perspective. One alternative is long-term abdominal drains (LTADs), used successfully in patients whose ascites is due to malignancy. Although inserted in hospital, these drains allow ascites management outside of a hospital setting. LTADs have not been formally evaluated in patients with refractory ascites due to ESLD. METHODS/DESIGN: Due to uncertainty about appropriate outcome measures and whether patients with ESLD would wish or be able to participate in a study, a feasibility randomised controlled trial (RCT) was designed. Patients were consulted on trial design. We plan to recruit 48 patients with refractory ascites and randomise them (1:1) to either (1) LTAD or (2) current standard of care (LVP) for 12 weeks. Outcomes of interest include acceptability of the LTAD to patients, carers and healthcare professionals as well as recruitment and retention rates. The Integrated Palliative care Outcome Scale, the Short Form Liver Disease Quality of Life questionnaire, the EuroQol 5 dimensions instrument and carer-reported (Zarit Burden Interview) outcomes will also be assessed. Preliminary data on cost-effectiveness will be collected, and patients and healthcare professionals will be interviewed about their experience of the trial with a view to identifying barriers to recruitment. DISCUSSION: LTADs could potentially improve end-of-life care in patients with refractory ascites due to ESLD by improving symptom control, reducing hospital visits and enabling some self-management. Our trial is designed to see if such patients can be recruited, as well as to inform the design of a subsequent definitive trial. TRIAL REGISTRATION: ISRCTN, ISRCTN30697116 . Registered on 7 October 2015.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Macken L, Mason L, Evans C, et al. Palliative long-term abdominal drains versus repeated drainage in individuals with untreatable ascites due to advanced cirrhosis: study protocol for a feasibility randomised controlled trial. Trials. 2018. PMID: 30053891. doi:10.1186/s13063-018-2779-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。